Exelixis to license Insilico AI-designed cancer drug
Exelixis Inc. (EXEL) is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insilico Medicine's generative artificial intelligence drug-discovery platform, the companies announced Tuesday. The cancer therapy, ISM3091, is an inhibitor of USP1 and is being studied for its potential to treat BRCA-mutant tumors, which include forms of ovarian, prostate and breast cancer. The deal gives Insilico an upfront payment of $80 million, expected in the third quarter of this year, and eligibility for future development, commercial and sales-based milestone payments. The agreement also gives Exelixis a license for other USP-1 targeting compounds, the companies said in a release. Exelixis shares gained 0.8% premarket on Tuesday and are up 37% in the year to date, while the S&P 500 has gained 16.9%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-12-23 0840ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst